27576906|t|Inactivation of Cancer Mutations Utilizing CRISPR/Cas9
27576906|a|Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.
27576906	16	32	Cancer Mutations	T038	UMLS:C1516197
27576906	43	54	CRISPR/Cas9	T038	UMLS:C3658355
27576906	64	87	whole-genome sequencing	T062	UMLS:C3640076
27576906	120	129	mutations	T038	UMLS:C0026882
27576906	141	154	tumorigenesis	T038	UMLS:C0596263
27576906	189	198	mutations	T038	UMLS:C0026882
27576906	276	291	tumor mutations	T038	UMLS:C1516197
27576906	302	313	CRISPR/Cas9	T038	UMLS:C3658355
27576906	339	344	sgRNA	T103	UMLS:C0082774
27576906	378	383	assay	T058	UMLS:C1510438
27576906	420	426	sgRNAs	T103	UMLS:C0082774
27576906	472	488	cancer mutations	T038	UMLS:C1516197
27576906	521	542	personalized medicine	T058	UMLS:C2718059